In Silico hERG modelling: Challenges and progress

Current Computer-Aided Drug Design

Volumn 5, Issue 2, 2009, Pages 106-121

  Diller, David J ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINITY;

BLOCKINGS; DRIVING FORCES; IN-SILICO; LIGAND BINDING; LIPOPHILICITY; SECOND GENERATION; TARGET BINDING;

BIOCHEMISTRY;

AZIMILIDE; BENZIMIDAZOLE; DOFETILIDE; IMIDAZOLE DERIVATIVE; NICOTINE; POTASSIUM CHANNEL HERG; QUINIDINE; TERFENADINE;

AMINO ACID SEQUENCE; BINDING AFFINITY; COMPUTER MODEL; COMPUTER PREDICTION; COMPUTER PROGRAM; CONCENTRATION RESPONSE; DRUG TARGETING; IC 50; INFORMATION PROCESSING; INTERMETHOD COMPARISON; LIGAND BINDING; LIPOPHILICITY; NONHUMAN; PHARMACOLOGICAL BLOCKING; PHARMACOPHORE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW;

EID: 70350225472     PISSN: 15734099     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340909788451928     Document Type: Review

References (145)

1. Yap, Y.G.; Camm, A.J. The current cardiac safety situation with antihistamines. Clin. Exp. Allergy, 1999, 29, 15-24.
2. De Ponti, F.; Poluzzi, E.; Montanaro, N. QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Eur. J. Clin. Pharmacol., 2000, 56, 1-18.
3. De Ponti, F.; Poluzzi, E.; Montanaro, N. Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus. Eur. J. Clin. Pharmacol., 2001, 57, 185-209.
4. De Ponti, F.; Poluzzi, E.; Vaccheri, A.; Bergman, U.; Bjerrum, L.; Ferguson, J.; Frenz, KJ.; McManus, P.; Schubert, I.; Selke, G.; Terzis-Vaslamatzis, G.; Montanaro, N. Non-antiarrhythmic drugs prolonging the QT interval: considerable use in seven countries. Br. J. Clin. Pharmacol., 2002, 54, 171-177.
5. De Ponti, F.; Poluzzi, E.; Cavalli, A.; Recanatini, M.; Montanaro, N. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Saf., 2002, 25, 263-286.
6. Haverkamp, W.; Breithardt, G.; Camm, A.J.; Janse, M.J.; Rosen, M.R.; Antzelevitch, C.; Escande, D.; Franz, M.; Malik, M.; Moss, A.; Shah, R. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc. Res., 2000, 47, 219-233.
7. Redfern, W.S.; Carlsson, L.; Davis, A.S.; Lynch, W.G.; MacKenzie, I.; Palethorpe, S.; Siegl, P.K.S.; Strang, I.; Sullivan, A.T.; Wallis, R.; Camm, A.J.; Hammond, T.G. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovas. Res., 2003, 58, 32-45.
8. Stevenson, J.P.; DeMaria, D.; Reilly, D.; Purvis, J.D.; Graham, M.A.; Lockwood, G.; Drozd, M.; O'Dwyer, P.J. Phase I/pharmacokinetic trial of the novel thioxanthone SR233377 (WIN33377) on a 5-day schedule. Cancer Chemother. Pharmacol., 1999, 44, 228-234.
9. Ulens, C.; Daenens, P.; Tytgat, J. Norpropoxyphene-induced cardiotoxicity is associated with changes in ion-selectivity and gating of HERG currents. Cardiovasc. Res., 1999, 44, 568-578.
10. Paakkari, I. Cardiotoxicity of new antihistamines and cisapride. Toxicol. Lett., 2002, 127, 279-284.
11. Dennis, A.; Wang, L.; Wan, X.; Ficker, E. hERG channel trafficking: novel targets in drug-induced long QT syndrome. Biochem. Soc. Trans., 2007, 35, 1060-1063.
12. Eckhardt, L.L.; Rajamani, S.; January, C.T. Protein trafficking abnormalities: a new mechanism in drug-induced long QT syndrome. Br. J. Pharmacol., 2005, 145, 3-4.
13. Hancox, J.C.; Mitcheson, J.S. Combined hERG channel inhibition and disruption of trafficking in drug-induced long QT syndrome by fluoxetine: a case-study in cardiac safety pharmacology. Br. J. Pharmacol., 2006, 149, 457-459.
14. Rajamani, S.; Eckhardt, L.L.; Valdivia, C.R.; Klemens, C.A.; Gillman, B.M.; Anderson, C.L.; Holzem, K.M.; Delisle, B.P.; Anson, B.D.; Makielski, J.C.; January, C.T. Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. Br. J. Pharmacol., 2006, 149, 481-489.
15. Takemasa, H.; Nagatomo, T.; Abe, H.; Kawakami, K.; Igarashi, T.; Tsurugi, T.; Kabashima, N.; Tamura, M.; Okazaki, M.; Delisle, B.P.; January, C.T.; Otsuji Y. Coexistence of hERG current block and disruption of protein trafficking in ketoconazole-induced long QT syndrome. Br. J. Pharmacol., 2008, 153, 439-447.
16. van der Heyden, M.A.; Smits, M.E.; Vos, M.A. Drugs and trafficking of ion channels: a new pro-arrhythmic threat on the horizon? Br. J. Pharmacol., 2008, 153, 406-409.
17. Waring, M.J.; Johnstone, C.A. quantitative assessment of hERG liability as a function of lipophilicity. Bioorg. Med. Chem. Lett., 2007, 17, 1759-1764.
18. Spencer, R.W. High-throughput screening of historic collections: observations on file size, biological targets, and file diversity. Biotechnol. Bioeng., 1998, 61, 61-67.
19. Jacoby, E.; Schuffenhauer, A.; Popov, M.; Azzaoui, K.; Havill, B.; Schopfer, U.; Engeloch, C.; Stanek, J.; Acklin, P.; Rigollier, P.; Stoll, F.; Koch, G.; Meier, P.; Orain, D.; Giger, R.; Hinrichs, J.; Malagu, K.; Zimmermann, J.; Roth, H.J. Key aspects of the Novartis compound collection enhancement project for the compilation of a comprehensive chemogenomics drug discovery screening collection. Curr. Top Med. Chem., 2005, 5, 397-411.
20. Ekins, S.; Crumb, W.J.; Sarazan, R.D.; Wikel, J.H.; Wrighton, S.A. Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. J. Pharmacol. Exp. Ther., 2002, 301, 427-434.
21. Roche, O.; Trube, G.; Zuegge, J.; Pflimlin, P.; Alanine, A.; Schneider, G. A virtual screening method for prediction of the HERG potassium channel liability of compound libraries. Chembiochem., 2002, 3, 455-459.
22. Johnson, S.R.; Yue, H.; Conder, M.L.; Shi, H.; Doweyko, A.M.; Lloyd, J.; Levesque, P. Estimation of hERG inhibition of drug candidates using multivariate property and pharmacophore SAR. Bioorg. Med. Chem., 2007, 15, 6182-6192.
23. Gleeson, M.P. Generation of a set of simple, interpretable ADMET rules of thumb. J. Med. Chem., 2008, 51, 817-834.
24. Kawai, M.; Ando, K.; Matsumoto, Y.; Sakurada, I.; Hirota, M.; Nakamura, H.; Ohta, A.; Sudo, M.; Hattori, K.; Takashima, T.; Hizue, M.; Watanabe, S.; Fujita, I.; Mizutani, M.; Kawamura, M.; Discovery of (-)-6-[2-[4-(3-fluorophenyl)-4-hydroxy-1-piperidinyl]-1- hydroxyethyl]-3,4-dihydro-2(1H)-quinolinone - a potent NR2B-selective N-methyl D-aspartate (NMDA) antagonist for the treatment of pain. Bioorg. Med. Chem. Lett., 2007, 17, 5558-5562.
25. Kawai, M.; Nakamura, H.; Sakurada, I.; Shimokawa, H.; Tanaka, H.; Matsumizu, M.; Ando, K.; Hattori, K.; Ohta, A.; Nukui, S.; Omura, A.; Kawamura, M. Discovery of novel and orally active NR2B-selective N-methyl-D-aspartate (NMDA) antagonists, pyridinol derivatives with reduced HERG binding affinity. Bioorg. Med. Chem. Lett., 2007, 17, 5533-5536.
26. Shamovsky, I.; Connolly, S.; David, L.; Ivanova, S.; Norden, B.; Springthorpe, B.; Urbahns K. Overcoming undesirable HERG potency of chemokine receptor antagonists using baseline lipophilicity relationships. J. Med. Chem., 2008, 51, 1162-1178.
27. Free, S.M. Jr.; Wilson, J.W. A Mathematical Contribution to Structure-Activity Studies. J. Med. Chem., 1964, 7, 395-399.
28. Maggiora, G.M. On outliers and activity cliffs - why QSAR often disappoints. J Chem. Inf. Model., 2006, 46, 1535.
29. Jamieson, C.; Moir, E.M.; Rankovic, Z.; Wishart, G. Medicinal chemistry of hERG optimizations: Highlights and hang-ups. J. Med. Chem., 2006, 49, 5029-5046.
30. Cavalli, A.; Poluzzi, E.; De Ponti, F.; Recanatini, M. Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers. J. Med. Chem., 2002, 45, 3844-3853.
31. Keseru, G.M. Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. Bioorg. Med. Chem. Lett., 2003, 13, 2773-2775.
32. Aronov, A.M.; Goldman, B.B. A model for identifying HERG K+ channel blockers. Bioorg. Med. Chem., 2004, 12, 2307-2315.
33. Aptula, A.O.; Cronin, M.T. Prediction of hERG K+ blocking potency: application of structural knowledge. SAR QSAR Environ. Res., 2004, 15, 399-411.
34. Bains, W.; Basman, A.; White, C. HERG binding specificity and binding site structure: evidence from a fragment-based evolutionary computing SAR study. Prog. Biophys. Mol. Biol., 2004, 86, 205-233.
35. Cianchetta, G.; Li, Y.; Kang, J.; Rampe, D.; Fravolini, A.; Cruciani, G.; Vaz, R.J. Predictive models for hERG potassium channel blockers. Bioorg. Med. Chem. Lett., 2005, 15, 3637-3642.
36. Tobita, M.; Nishikawa, T.; Nagashima, R. A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors. Bioorg. Med. Chem. Lett., 2005, 15, 2886-2890.
37. Aronov, A.M. Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) blockers. J. Med. Chem., 2006, 49, 6917-6921.
38. Coi, A.; Massarelli, I.; Murgia, L.; Saraceno, M.; Calderone, V. Bianucci AM. Prediction of hERG potassium channel affinity by the CODESSA approach. Bioorg. Med. Chem., 2006, 14, 3153-3159.
39. Dubus, E.; Ijjaali, I.; Petitet, F.; Michel, A. In silico classification of HERG channel blockers: a knowledge-based strategy. ChemMed-Chem., 2006, 1, 622-630.
40. Ekins, S.; Balakin, K.V.; Savchuk, N.; Ivanenkov, Y. Insights for human ether-a-go-go-related gene potassium channel inhibition using recursive partitioning and Kohonen and Sammon mapping techniques. J. Med. Chem., 2006, 49, 5059-5071.
41. Gepp, M.M.; Hutter, M.C. Determination of hERG channel blockers using a decision tree. Bioorg. Med. Chem., 2006, 14, 5325-5332.
42. Seierstad, M.; Agrafiotis, D.K. A QSAR model of HERG binding using a large, diverse, and internally consistent training set. Chem. Biol. Drug Des., 2006, 67, 284-296.
43. Song, M.; Clark, M. Development and evaluation of an in silico model for hERG binding. J. Chem. Inf. Model., 2006, 46, 392-400.
44. Sun, H. An accurate and interpretable bayesian classification model for prediction of HERG liability. ChemMedChem., 2006, 1, 315-322.
45. Yoshida, K.; Niwa, T. Quantitative structure-activity relationship studies on inhibition of HERG potassium channels. J. Chem. Inf. Model., 2006, 46, 1371-1378.
46. Diller, D.J.; Hobbs, D.W. Understanding hERG inhibition with QSAR models based on a one-dimensional molecular representation. J. Comput. Aided Mol. Des., 2007, 21, 379-393.
47. Gavaghan, C.L.; Arnby, C.H.; Blomberg, N.; Strandlund, G.; Boyer, S. Development, interpretation and temporal evaluation of a global QSAR of hERG electrophysiology screening data. J. Comput. Aided Mol. Des., 2007, 21, 189-206.
48. Leong, M.K. A novel approach using pharmacophore ensemble/support vector machine (PhE/SVM) for prediction of hERG liability. Chem. Res. Toxicol., 2007, 20, 217-226.
49. Chekmarev, D.S.; Kholodovych, V.; Balakin, K.V.; Ivanenkov, Y.; Ekins, S.; Welsh, W.J. Shape signatures: new descriptors for predicting cardiotoxicity in silico. Chem. Res. Toxicol., 2008.
50. Coi, A.; Massarelli, I.; Testai, L.; Calderone, V.; Bianucci, A.M. Identification of "toxicophoric" features for predicting drug-induced QT interval prolongation. Eur. J. Med. Chem., 2008.
51. Garg, D.; Gandhi, T.; Gopi Mohan, C. Exploring QSTR and toxicophore of hERG K+ channel blockers using GFA and HypoGen techniques. J. Mol. Graph Model, 2008, 26, 966-976.
52. Jia, L.; Sun, H. Support vector machines classification of hERG liabilities based on atom types. Bioorg. Med. Chem., 2008, 16, 6252-6260.
53. Witchel, H.J.; Milnes, J.T.; Mitcheson, J.S.; Hancox, J.C. Trouble-shooting problems with in vitro screening of drugs for QT interval prolongation using HERG K+ channels expressed in mammalian cell lines and Xenopus oocytes. J. Pharmacol. Toxicol. Methods, 2002, 48, 65-80.
54. Diaz, G. J.; Daniell, K.; Leitza, S. T.; Martin, R. L.; Su, Z.; McDermott, J.S.; Cox, B.F.; Gintant, G.A. The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o. J. Pharmacol. Toxicol. Methods, 2004, 50, 187-199.
55. Finlayson, K.; Sharkey, J. A high-throughput binding assay for HERG. Optim. Drug Discov., 2004, 353-368.
56. Finlayson, K.; Turnbull, L.; January, C.T.; Sharkey, J.; Kelly, J.S. [3H]dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen. Eur. J. Pharmacol., 2001, 430, 147-148.
57. Chiu, P.J.; Marcoe, K.F.; Bounds, S.E.; Lin, C.H.; Feng, J.J.; Lin, A.; Cheng, F.C.; Crumb, W.J.; Mitchell R. Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels. J. Pharmacol. Sci., 2004, 95, 311-319.
58. Cheng, C.S.; Alderman, D.; Kwash, J.; Dessaint, J.; Patel, R.; Lescoe, M.K.; Kinrade, M.B.; Yu, W. A high-throughput HERG potassium channel function assay: an old assay with a new look. Drug Dev. Ind. Pharm., 2002, 28, 177-191.
59. Rezazadeh, S.; Hesketh, J.C.; Fedida, D. Rb+ flux through hERG channels affects the potency of channel blocking drugs: correlation with data obtained using a high-throughput Rb+ efflux assay. J. Biomol. Screen., 2004, 9, 588-597.
60. Tang, W.; Kang, J.; Wu, X.; Rampe, D.; Wang, L. Shen, H.; Li, Z.; Dunnington, D.; Garyantes T. Development and evaluation of high throughput functional assay methods for HERG potassium channel. J. Biomol. Screen., 2001, 6, 325-331.
61. Schroeder, K.; Neagle, B.; Trezise, D.J.; Worley, J. Ionworks HT: a new high-throughput electrophysiology measurement platform. J. Biomol. Screen., 2003, 8, 50-64.
62. Bridgland-Taylor, M.H.; Hargreaves, A.C.; Easter, A.; Orme, A.; Henthorn, D.C.; Ding, M.; Davis, A.M.; Small, B.G.; Heapy, C.G.; Abi-Gerges, N.; Persson, F.; Jacobson, I.; Sullivan, M.; Albertson, N.; Hammond, T.G.; Sullivan, E.; Valentin, J.P. Pollard CE Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT. J. Pharmacol. Toxicol. Methods, 2006, 54, 189-199.
63. Taglialatela, M.; Pannaccione, A.; Castaldo, P.; Giorgio, G.; Zhou, Z.; January, C.T.; Genovese, A.; Marone, G.; Annunziato, L. Molecular basis for the lack of HERG K+ channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines. Mol. Pharmacol., 1998, 54, 113-121.
64. Suessbrich, H.; Waldegger, S.; Lang, F.; Busch, A.E. Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett., 1996, 385, 77-80.
65. Chachin, M.; Katayama, Y.; Yamada, M.; Horio, Y.; Ohmura, T.; Kitagawa, H.; Uchida, S.; Kurachi, Y. Epinastine, a nonsedating histamine H1 receptor antagonist, has a negligible effect on HERG channel. Eur. J. Pharmacol., 1999, 374, 457-460.
66. Rampe, D.; Murawsky, M.K.; Grau, J.; Lewis, E.W. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. J. Pharmacol. Exp. Ther., 1998, 286, 788-793.
67. Rampe, D.; Roy, M.L.; Dennis, A.; Brown, A.M. A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG. FEBS Lett., 1997, 417, 28-32.
68. Snyders, D.J.; Chaudhary, A. High affinity open channel block by dofetilide of HERG expressed in a human cell line. Mol. Pharmacol., 1996, 49, 949-955.
69. Crumb, W.J. Jr. Loratadine blockade of K(+) channels in human heart: comparison with terfenadine under physiological conditions. J. Pharmacol. Exp. Ther., 2000, 292, 261-264.
70. Topliss, J.G.; Edwards, R.P. Chance factors in studies of quantitative structure-activity relationships. J. Med. Chem., 1979, 22, 1238-1244.
71. Ertl, P.; Rohde, B.; Selzer, P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J. Med. Chem., 2000, 43, 3714-3717.
72. Pearlstein, R.A.; Vaz, R.J.; Kang, J.; Chen, X.L.; Preobrazhenskaya, M.; Shchekotikhin, A.E.; Korolev, A.M.; Lysenkova, L.N.; Miroshnikova, O.V.; Hendrix, J.; Rampe, D. Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. Bioorg. Med. Chem. Lett., 2003, 13, 1829-1835.
73. Kier, L.B.; Hall, L.H. An electrotopological-state index for atoms in molecules. Pharm. Res., 1990, 7, 801-807.
74. Mitcheson, J.S. hERG potassium channels and the structural basis of drug-induced arrhythmias. Chem. Res. Toxicol., 2008, 21, 1005-1010.
75. Long, S.B.; Campbell, E.B.; Mackinnon, R. Crystal structure of a mammalian voltage-dependent Shaker family K+ channel. Science, 2005, 309, 897-903.
76. Long, S.B.; Tao, X.; Campbell, E.B.; MacKinnon, R. Atomic structure of a voltage-dependent K+ channel in a lipid membrane-like environment. Nature, 2007, 450, 376-382.
77. Zhou, Y.; Morais-Cabral, J.H.; Kaufman, A.; MacKinnon, R. Chemistry of ion coordination and hydration revealed by a K+ channel-Fab complex at 2.0 A resolution. Nature, 2001, 414, 43-48.
78. Jiang, Y.; Lee, A.; Chen, J.; Ruta, V.; Cadene, M.; Chait, B.T.; MacKinnon R. X-ray structure of a voltage-dependent K+ channel. Nature, 2003, 423, 33-41.
79. Lee, S.Y.; Lee, A.; Chen, J.; MacKinnon, R. Structure of the KvAP voltage-dependent K+ channel and its dependence on the lipid membrane. Proc. Natl. Acad. Sci. USA, 2005, 102, 15441-15446.
80. Jiang, Y.; Lee, A.; Chen, J.; Cadene, M.; Chait, B.T.; MacKinnon, R. Crystal structure and mechanism of a calcium-gated potassium channel. Nature, 2002, 417, 515-522.
81. Sansom, M.S.P. Ion channels: Structure of a molecular brake. Curr. Biol. 1999, 9, R173-R175.
82. Suessbrich, H.; Schonherr, R.; Heinemann, S.H.; Lang, F.; Busch, AE. Specific block of cloned Herg channels by clofilium and its tertiary analog LY97241. FEBS Lett., 1997, 414, 435-438.
83. Ficker, E.; Jarolimek, W.; Kiehn, J.; Baumann, A.; Brown, A.M. Molecular determinants of dofetilide block of HERG K+ channels. Circ. Res., 1998, 82, 386-395.
84. Wang, H.; Shi, H.; Wang, Z. Inactivation block of the HERG human cardiac K+ channels by RP58866. Br. J. Pharmacol., 1999, 127, 1899-1907.
85. Wang, H.Z.; Shi, H.; Liao, S.J.; Wang, Z. Inactivation gating determines nicotine blockade of human HERG channels. Am. J. Physiol., 1999, 277, H1081-1088.
86. Zhang, S.; Zhou, Z.; Gong, Q.; Makielski, J.C.; January, C.T. Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circ. Res., 1999, 84, 989-998.
87. Mitcheson, J.S.; Chen, J.; Lin, M.; Culberson, C.; Sanguinetti, M.C. A structural basis for drug-induced long QT syndrome. Proc. Natl. Acad. Sci. USA, 2000, 97, 12329-12333.
88. Mitcheson, J.S.; Chen, J.; Sanguinetti, M.C. Trapping of a methane-sulfonanilide by closure of the HERG potassium channel activation gate. J. Gen. Physiol., 2000, 115, 229-240.
89. Lees-Miller, J.P.; Duan, Y.; Teng, G.Q.; Duff, H.J. Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites. Mol. Pharmacol., 2000, 57, 367-374.
90. Thomas, D.; Wendt-Nordahl, G.; Rockl, K.; Ficker, E.; Brown, A.M.; Kiehn, J. High-affinity blockade of human ether-a-go-go-related gene human cardiac potassium channels by the novel antiarrhythmic drug BRL-32872. J. Pharmacol. Exp. Ther., 2001, 297, 753-761.
91. Paul, A.A.; Witchel, H.J.; Hancox, J.C. Inhibition of HERG potassium channel current by the class 1a antiarrhythmic agent disopyramide. Biochem. Biophys. Res. Commun., 2001, 280, 1243-1250.
92. Chen, J.; Seebohm, G.; Sanguinetti, M.C. Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels. Proc. Natl. Acad. Sci. USA, 2002, 99, 12461-12466.
93. Sanchez-Chapula, J.A.; Navarro-Polanco, R.A.; Culberson, C.; Chen, J.; Sanguinetti, M.C. Molecular determinants of voltage-dependent human ether-a-go-go related gene (HERG) K+ channel block. J. Biol. Chem., 2002, 277, 23587-23595.
94. Weerapura, M.; Hebert, T.E.; Nattel, S. Dofetilide block involves interactions with open and inactivated states of HERG channels. Pflugers. Arch., 2002, 443, 520-531.
95. Gessner, G.; Heinemann, S.H. Inhibition of hEAG1 and hERG1 potassium channels by clofilium and its tertiary analogue LY97241. Br. J. Pharmacol., 2003, 138, 161-171.
96. Ishii, K.; Nagai, M.; Takahashi, M.; Endoh, M. Dissociation of E-4031 from the HERG channel caused by mutations of an amino acid results in greater block at high stimulation frequency. Cardiovas. Res., 2003, 57, 651-659.
97. Fernandez, D.; Ghanta, A.; Kauffman, G.W.; Sanguinetti, M.C. Physicochemical features of the HERG channel drug binding site. J. Biol. Chem., 2004, 279, 10120-10127.
98. Ridley, J.M.; Milnes, J.T.; Witchel, H.J.; Hancox, J.C. High affinity HERG K(+) channel blockade by the antiarrhythmic agent dronedarone: resistance to mutations of the S6 residues Y652 and F656. Biochem. Biophys. Res. Commun., 2004, 325, 883-891.
99. Perry, M.; de Groot, M.J.; Helliwell, R.; Leishman, D.; Tristani-Firouzi, M.; Sanguinetti M.C.; Mitcheson J. Structural determinants of HERG channel block by clofilium and ibutilide. Mol. Pharmacol., 2004, 66, 240-249.
100. Yang, B.-f.; Xu, D.-h.; Xu, C.-q.; Li, Z.; Du, Z.-m.; Wang, H-z.; Dong, D-l. Inactivation gating determines drug potency: A common mechanism for drug blockade of HERG channels. Acta Pharmacol. Sinica, 2004, 25, 554-560.
101. Milnes, J.T.; Witchel, H.J.; Leaney, J.L.; Leishman, D.J.; Hancox, J.C. hERG K+ channel blockade by the antipsychotic drug thioridazine: An obligatory role for the S6 helix residue F656. Biochem. Biophys. Res. Commun., 2006, 351, 273-280.
102. Su, Z.; Chen, J.; Martin, R.L.; McDermott, J.S.; Cox, B.F. Gopalakrishnan, M.; Gintant, G.A. Block of hERG channel by ziprasidone: biophysical properties and molecular determinants. Biochem. Pharmacol., 2006, 71, 278-286.
103. Sanguinetti, M.C.; Tristani-Firouzi, M. hERG potassium channels and cardiac arrhythmia. Nature, 2006, 440, 463-469.
104. Duncan, R.S.; McPate, M.J.; Ridley, J.M.; Gao, Z.; James, A.F.; Leishman, D.J.; Leaney, J.L.; Witchel, H.J.; Hancox, J.C. Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin. Biochem. Pharmacol., 2007, 74, 425-437.
105. Luo, T.; Luo, A.; Liu, M.; Liu, X. Inhibition of the HERG channel by droperidol depends on channel gating and involves the S6 residue F656. Anesth. Analg., 2008, 106, 1161-1170, (Table of Contents).
106. Hancox, J.C.; Witchel, H.J.; Varghese, A. Alteration of HERG current profile during the cardiac ventricular action potential, following a pore mutation. Biochem. Biophys. Res. Commun., 1998, 253, 719-724.
107. Sanguinetti, M.C.; Mitcheson, J.S. Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol. Sci., 2005, 26, 119-124.
108. Zou, A.; Curran, M.E.; Keating, M.T.; Sanguinetti, M.C. Single HERG delayed rectifier K+ channels expressed in Xenopus oocytes. Am. J. Physiol., 1997, 272, H1309-1314.
109. Rajamani, R.; Tounge, B.A.; Li, J.; Reynolds, C.H. A two-state homology model of the hERG K+ channel: application to ligand binding. Bioorg. Med. Chem. Lett., 2005, 15, 1737-1741.
110. Choe, H.; Nah, K.H.; Lee, S.N.; Lee, H.S.; Jo, S.H.; Leem, C.H.; Jang, Y.J. A novel hypothesis for the binding mode of HERG channel blockers. Biochem. Biophys. Res. Commun., 2006, 344, 72-78.
111. Farid, R.; Day, T.; Friesner, R.A.; Pearlstein, R.A. New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies. Bioorg. Med. Chem., 2006, 14, 3160-3173.
112. Du, L.; Li, M.; You, Q.; Xia, L. A novel structure-based virtual screening model for the hERG channel blockers. Biochem. Biophys. Res. Commun., 2007, 355, 889-894.
113. Stansfeld, P.J.; Gedeck, P.; Gosling, M.; Cox, B.; Mitcheson, J.S.; Sutcliffe, M.J. Drug block of the hERG potassium channel: insight from modeling. Proteins, 2007, 68, 568-580.
114. Masetti, M.; Cavalli, A.; Recanatini, M. Modeling the hERG potassium channel in a phospholipid bilayer: Molecular dynamics and drug docking studies. J. Comput. Chem., 2008, 29, 795-808.
115. Roux, B.; MacKinnon, R. The cavity and pore helices in the KcsA K+ channel: electrostatic stabilization of monovalent cations. Science, 1999, 285, 100-102.
116. Zhu, B.Y.; Jia, Z.J.; Zhang, P.; Su, T.; Huang, W.; Goldman, E.; Tumas, D.; Kadambi, V.; Eddy, P.; Sinha, U.; Scarborough, R.M.; Song Y. Inhibitory effect of carboxylic acid group on hERG binding. Bioorg. Med. Chem. Lett., 2006, 16, 5507-5512.
117. Ekroos, M.; Sjogren, T. Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc. Natl. Acad. Sci. USA, 2006, 103, 13682-13687.
118. Watkins, R.E.; Noble, S.M.; Redinbo, M.R. Structural insights into the promiscuity and function of the human pregnane X receptor. Curr. Opin. Drug Discov. Devel., 2002, 5, 150-158.
119. Watkins, R.E.; Wisely, G.B.; Moore, L.B.; Collins, J.L.; Lambert, M.H.; Williams, S.P.; Willson, T.M.; Kliewer, S.A.; Redinbo MR. The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science, 2001, 292, 2329-2333.
120. Zhu, L.; Yang, F.; Chen, L.; Meehan, E.J.; Huang, M. A new drug binding subsite on human serum albumin and drug-drug interaction studied by X-ray crystallography. J. Struct. Biol., 2008, 162, 40-49.
121. Lejon, S.; Cramer, J.F.; Nordberg, P. Structural basis for the binding of naproxen to human serum albumin in the presence of fatty acids and the GA module. Acta Crystallogr. Sect. F. Struct. Biol. Cryst. Commun., 2008, 64, 64-69.
122. Zunszain, P.A.; Ghuman, J.; McDonagh, A.F.; Curry, S. Crystallographic analysis of human serum albumin complexed with 4Z,15E-bilirubin-IXalpha. J. Mol. Biol., 2008, 381, 394-406.
123. Fujiwara, S.; Amisaki, T. Molecular dynamics study of conformational changes in human serum albumin by binding of fatty acids. Proteins, 2006, 64, 730-739.
124. Loo, T.W.; Bartlett, M.C.; Clarke, D.M. Substrate-induced conformational changes in the transmembrane segments of human P-glycoprotein. Direct evidence for the substrate-induced fit mechanism for drug binding. J. Biol. Chem., 2003, 278, 13603-13606.
125. Kang, J.; Wang, L.; Chen, X.L.; Triggle, D.J.; Rampe, D. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol. Pharmacol., 2001, 59, 122-126.
126. Anderson, M.E.; Mazur, A.; Yang, T.; Roden, D.M. Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics. J. Pharmacol. Exp. Ther., 2001, 296, 806-810.
127. Rubinstein, E.; Camm, J. Cardiotoxicity of fluoroquinolones. J. Antimicrob. Chemother., 2002, 49, 593-596.
128. Iyengar, R.R.; Lynch, J.K.; Mulhern, M.M.; Judd, A.S.; Freeman, J.C.; Gao, J.; Souers, A.J.; Zhao, G.; Wodka, D.; Doug Falls, H.; Brodjian, S.; Dayton, B.D.; Reilly, R.M.; Swanson, S.; Su Z, Martin R.L.; Leitza S.T.; Houseman, K.A.; Diaz, G.; Collins, C.A.; Sham, H.L.; Kym, P.R. An evaluation of 3,4-methylenedioxy phenyl replacements in the aminopiperidine chromone class of MCHr1 antagonists. Bioorg. Med. Chem. Lett., 2007, 17, 874-878.
129. Graham, J.M.; Coughenour, L.L.; Barr, B.M.; Rock, D.L.; Nikam, S.S. 1-Aminoindanes as novel motif with potential atypical antipsychotic properties. Bioorg. Med. Chem. Lett., 2008, 18, 489-493.
130. Kort, M.E.; Drizin, I.; Gregg, R.J.; Scanio, M.J.; Shi, L.; Gross, M.F.; Atkinson, R.N.; Johnson, M.S.; Pacofsky, G.J.; Thomas, J.B.; Carroll, W.A.; Krambis, M.J.; Liu, D.; Shieh, C.C.; Zhang, X.; Hernandez, G.; Mikusa, J.P.; Zhong, C.; Joshi, S.; Honore, P.; Roeloffs, R.; Marsh, K.C.; Murray, B.P.; Liu, J.; Werness, S.; Faltynek, C.R.; Krafte, D.S.; Jarvis, M.F.; Chapman, M.L.; Marron, B.E. Discovery and biological evaluation of 5-aryl-2-furfuramides, potent and selective blockers of the Nav1.8 sodium channel with efficacy in models of neuropathic and inflammatory pain. J. Med. Chem., 2008, 51, 407-416.
131. Moorjani, M.; Zhang, X.; Chen, Y.; Lin, E.; Rueter, J.K.; Gross, R.S.; Lanier, M.C.; Tellew, J.E.; Williams, J.P.; Lechner, S.M.; Malany, S.; Santos, M.; Ekhlassi, P.; Castro-Palomino, J.C.; Crespo, M.I.; Prat, M.; Gual, S.; Diaz, J.L.; Saunders, J.; Slee, D.H. 2,6-Diaryl-4-phenacylaminopyrimidines as potent and selective adenosine A(2A) antagonists with reduced hERG liability. Bioorg. Med. Chem. Lett., 2008, 18, 1269-1273.
132. Thoma, G.; Beerli, C.; Bigaud, M.; Bruns, C.; Cooke, N.G.; Streiff, M.B.; Zerwes, H.G. Reduced cardiac side-effect potential by introduction of polar groups: discovery of NIBR-1282, an orally bioavailable CCR5 antagonist which is active in vivo. Bioorg. Med. Chem. Lett., 2008,, 18, 2000-2005.
133. Slee, D.H.; Moorjani, M.; Zhang, X.; Lin, E.; Lanier, M.C.; Chen, Y.; Rueter, J.K.; Lechner, S.M.; Markison, S.; Malany, S.; Joswig, T.; Santos, M.; Gross, R.S.; Williams, J.P.; Castro-Palomino J.C.; Crespo, M.I.; Prat, M.; Gual, S.; Diaz, J.L.; Jalali, K.; Sai, Y.; Zuo, Z.; Yang, C.; Wen, J.; O'Brien, Z.; Petroski, R.; Saunders, J. 2-Amino-N-pyrimidin-4-ylacetamides as A2A receptor antagonists: 2. Reduction of hERG activity, observed species selectivity, and structure-activity relationships. J. Med. Chem., 2008, 51, 1730-1739.
134. Whitlock, G.A.; Blagg, J.; Fish, P.V. 1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity. Bioorg. Med. Chem. Lett., 2008, 18, 596-599.
135. Yoshizumi, T.; Takahashi, H.; Miyazoe, H.; Sugimoto, Y.; Tsujita, T.; Kato, T.; Ito, H.; Kawamoto, H.; Hirayama, M.; Ichikawa, D.; Azuma-Kanoh, T.; Ozaki, S.; Shibata, Y.; Tani, T.; Chiba, M.; Ishii, Y.; Okuda, S.; Tadano, K.; Fukuroda, T.; Okamoto, O.; Ohta, H. A Novel Class of Cycloalkano[b]pyridines as Potent and Orally Active Opioid Receptor-like 1 Antagonists with Minimal Binding Affinity to the hERG K(+) Channel. J. Med. Chem., 2008.
136. Cox, J.M.; Harper, B.; Mastracchio, A.; Leiting, B.; Sinha Roy, R.; Patel, R.A.; Wu, J.K.; Lyons, K.A.; He, H.; Xu, S.; Zhu, B.; Thornberry, N.A.; Weber, A.E.; Edmondson, S.D. Discovery of 3-aminopiperidines as potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett 2007, 17, 4579-4583.
137. Dinges, J.; Albert, D.H.; Arnold, L. D.; Ashworth, K.L.; Akritopoulou-Zanze, I.; Bousquet, P.F.; Bouska, J.J.; Cunha, G.A.; Davidsen, S.K.; Diaz, G.J.; Djuric, S.W.; Gasiecki, A.F.; Gintant, G.A.; Gracias, V.J.; Harris, C.M.; Houseman, K.A.; Hutchins, C.W.; Johnson, E.F.; Li, H.; Marcotte, P.A.; Martin, R.L.; Michaelides, M.R.; Nyein, M.; Sowin, T.J.; Su, Z.; Tapang, P.H.; Xia, Z.; Zhang, H.Q. 1,4-Dihydroindeno[1,2-c]pyrazoles with acetylenic side chains as novel and potent multitargeted receptor tyrosine kinase inhibitors with low affinity for the hERG ion channel. J. Med. Chem., 2007, 50, 2011-2029.
138. Judd, A.S.; Souers, A.J.; Wodka, D.; Zhao, G.; Mulhern, M.M.; Iyengar, R.R.; Gao, J.; Lynch, J.K.; Freeman, J.C.; Falls, H.D.; Brodjian, S.; Dayton, B.D.; Reilly, R.M.; Gintant, G.; Limberis, J.T.; Mikhail, A.; Leitza, S.T.; Houseman, K.A.; Diaz, G.; Bush, E.N.; Shapiro, R.; Knourek-Segel, V.; Hernandez, L.E.; Marsh, K.C.; Sham, H.L.; Collins, C.A.; Kym, P.R. Identification of diamino chromone-2-carboxamides as MCHr1 antagonists with minimal hERG channel activity. Bioorg. Med. Chem. Lett., 2007, 17, 2365-2371.
139. Alberati, D.; Hainzl, D.; Jolidon, S.; Krafft, E.A.; Kurt, A.; Maier, A.; Pinard, E.; Thomas, A.W.; Zimmerli, D. Discovery of 4-substituted-8-(2-hydroxy-2-phenyl-cyclohexyl)-2, 8-diaza-spiro[4.5]decan-1-one as a novel class of highly selective GlyT1 inhibitors with improved metabolic stability. Bioorg. Med. Chem. Lett., 2006, 16, 4311-4315.
140. Liverton, N.J.; Bednar, R.A.; Bednar, B.; Butcher, J.W.; Claiborne, C.F.; Claremon, D.A.; Cunningham, M.; DiLella, A.G.; Gaul, S.L.; Libby, B.E.; Lyle, E.A.; Lynch, J.J.; McCauley, J.A.; Mosser, S.D.; Nguyen, K.T.; Stump, G.L.; Sun, H.; Wang, H.; Yergey, J.; Koblan, K.S. Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist. J. Med. Chem., 2007, 50, 807-819.
141. Lowe, J.; Drozda, S.; Qian, W.; Peakman, M.C.; Liu, J. Gibbs, J.; Harms, J.; Schmidt, C.; Fisher, K.; Strick, C.; Schmidt, A.; Vanase, M.; Lebel, L. A novel, non-substrate-based series of glycine type 1 transporter inhibitors derived from high-throughput screening. Bioorg. Med. Chem. Lett., 2007, 17, 1675-1678.
142. Meyers, K.M.; Mendez-Andino, J.L.; Colson, A.O.; Warshakoon, N.C.; Wos, J.A.; Mitchell, M.C.; Hodge, K.M.; Howard, J.M.; Ackley DC, Holbert JK, Mittelstadt, S.W.; Dowty, M.E.; Obringer, C.M.; Reizes, O.; Hu, X.E. Aminomethyl tetrahydronaphthalene ketopiperazine MCH-R1 antagonists - Increasing selectivity over hERG. Bioorg. Med. Chem. Lett., 2007, 17, 819-822.
143. Mendez-Andino, J.L.; Colson, A.O.; Meyers, K.M.; Mitchell, M.C.; Hodge, K.; Howard, J.M.; Kim, N.; Ackley, D.C.; Holbert, J.K.; Mittelstadt, S.W.; Dowty, M.E.; Obringer, C.M.; Suchanek, P.; Reizes, O.; Hu, X.E.; Wos, J.A. The efficacy and cardiac evaluation of aminomethyl tetrahydronaphthalene ketopiperazines: a novel class of potent MCH-R1 antagonists. Bioorg. Med. Chem., 2007, 15, 2092-2105.
144. Meyers, K.M.; Kim, N.; Mendez-Andino, J.L.; Hu, X.E.; Mumin, R.N.; Klopfenstein, S.R.; Wos, J.A.; Mitchell, M.C.; Paris, J.L.; Ackley, D.C.; Holbert, J.K.; Mittelstadt, S.W.; Reizes, O. Aminomethyl tetrahydronaphthalene biphenyl carboxamide MCH-R1 antagonists - Increasing selectivity over hERG. Bioorg. Med. Chem. Lett., 2007, 17, 814-818.
145. Souers, A.J.; Iyengar, R.R.; Judd, A.S.; Beno, D.W.; Gao, J.; Zhao, G.; Brune, M.E.; Napier, J.J.; Mulhern, M.M.; Lynch, J.K.; Freeman, J.C.; Wodka, D.; Chen, C.J.; Falls, H.D.; Brodjian, S.; Dayton, B.D.; Diaz, G.J.; Bush, E.N.; Shapiro, R.; Droz, B.A.; Knourek-Segel, V.; Hernandez, L.E.; Marsh, K.C.; Reilly, R.M.; Sham, H.L.; Collins, C.A.; Kym, P.R. Constrained 7-fluorocarboxychromone-4-aminopiperidine based Melanin-concentrating hormone receptor 1 antagonists: the effects of chirality on substituted indan-1-ylamines. Bioorg. Med. Chem. Lett., 2007, 17, 884-889.